Fidelis Capital Partners’s AbbVie ABBV Stock Holding History

Fidelis Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.34M	Sell	33,736 -385	-1%	-$85.4K	0.52%	40
2025 Q4	$7.8M	Buy	34,121 +1,796	+6%	+$409K	0.57%	38
2025 Q3	$7.48M	Buy	32,325 +3,951	+14%	+$805K	0.58%	35
2025 Q2	$5.57M	Sell	28,374 -145	-0.5%	-$26.9K	0.51%	38
2025 Q1	$5.31M	Buy	28,519 +1,560	+6%	+$303K	0.56%	35
2024 Q4	$5.13M	Buy	26,959 +2,214	+9%	+$407K	0.51%	39
2024 Q3	$4.65M	Buy	24,745 +1,778	+8%	+$332K	0.55%	35
2024 Q2	$4.31M	Buy	22,967 +2,347	+11%	+$389K	0.61%	32
2024 Q1	$3.75M	Buy	20,620 +4,456	+28%	+$768K	0.57%	35
2023 Q4	$2.5M	Buy	16,164 +2,607	+19%	+$380K	0.55%	36
2023 Q3	$2.02M	Buy	13,557 +2,187	+19%	+$321K	0.69%	31
2023 Q2	$1.53M	Buy	11,370 +678	+6%	+$99.4K	0.56%	41
2023 Q1	$1.58M	Buy	10,692 +7,602	+246%	+$1.16M	0.67%	35
2022 Q4	$500K	Buy	+3,090	New	+$474K	0.59%	58

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelis Capital Partners's ABBV Position: Q1 2026 in Review

Fidelis Capital Partners reduced its AbbVie (ABBV) stake by 1.1% in Q1 2026, selling an estimated $85.4K and leaving 33,736 shares worth $7.34M. The position accounts for 0.52% of the portfolio, ranked #40.

Fidelis Capital Partners first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $7.8M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Fidelis Capital Partners held 33,736 shares of AbbVie worth $7.34M as of Q1 2026.
Fidelis Capital Partners sold 385 AbbVie shares in Q1 2026, an estimated $85.4K.
AbbVie made up 0.52% of Fidelis Capital Partners's portfolio in Q1 2026, its #40 holding.
Fidelis Capital Partners first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Fidelis Capital Partners's AbbVie position peaked at $7.8M in Q4 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.